Details of the Drug

General Information of Drug (ID: DMBT3AI)

Drug Name
Belantamab mafodotin
Indication
Disease Entry ICD 11 Status REF
Multiple myeloma 2A83 Approved [1]
Drug Type
Antibody drug conjugate
ADMET Property
Absorption AUC
The area under the plot of plasma concentration (AUC) of drug is 4666 mgh/L [2]
Absorption Cmax
The maximum plasma concentration (Cmax) of drug is 42 mg/L [2]
Absorption Tmax
The time to maximum plasma concentration (Tmax) is 0.78 h [2]
Clearance
The clearance of drug is 0.9 L/day [2]
Half-life
The concentration or amount of drug in body reduced by one-half in 12 days [2]
Metabolism
The drug is metabolized via oxidation and demethylation, however further data is not readily available [2]
Vd
The volume of distribution (Vd) of drug is 11 L [2]
Cross-matching ID
DrugBank ID
DB15719
TTD ID
D52NZX

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
B-cell maturation protein (TNFRSF17) TTZ3P4W TNR17_HUMAN Not Available [1]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

References

1 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
2 FDA Approved Drug Products: Blenrep Belantamab Mafodotin-blmf Intravenous Injection